Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

NCT01799889 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01799889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01799889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
March 14, 2013
Completion date
January 30, 2020
Enrollment
326 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, non-fl indolent non-hodgkin's lymphoma